Internal Medicine, Endocrinology, Diabetes, & Metabolism · Indianapolis, IN
NPI
1639270721
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
9240 N Meridian St, Suite 240
Indianapolis, IN, 46260
Phone (317) 571-0030
Groups this clinician bills Medicare through
Medicare paid, 2024
$48K
4,380 services
Medicare patients, 2024
220
Average age 73
Drug cost, 2024
$2.0M
4,002 prescriptions
Company payments, 2025
$2,711
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Moazzam W Habib was code 99214 (office e&m - established), 270 times for 111 patients. In total Moazzam W Habib billed 4,380 services in 20 codes, and Medicare paid $48K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 270 | 111 | $77.91 | $21K |
| 99231 Hospital E&M - Subsequent | Facility | 111 | 43 | $33.95 | $3,768 |
| 99232 Hospital E&M - Subsequent | Facility | 99 | 39 | $53.13 | $5,260 |
| 99215 Office E&M - Established | Office | 36 | 27 | $117.72 | $4,238 |
| 99223 Hospital E&M - Initial | Facility | 35 | 35 | $120.50 | $4,218 |
| 99308 SNF E&M | Office | 28 | 25 | $51.95 | $1,455 |
By year: 2022 $88K for 1,424 services; 2023 $67K for 3,197 services; 2024 $48K for 4,380 services.
Medicare prescription drug claims, 2024
In 2024, the drug Moazzam W Habib prescribed most often to Medicare patients was Synthroid (Levothyroxine Sodium), with 213 prescriptions and refills. In total Moazzam W Habib wrote 4,002 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Synthroid Levothyroxine Sodium | 213 | 463 | 37 | $17K |
| Metformin Hcl Generic | 193 | 338 | 40 | $2,508 |
| Levothyroxine Sodium Generic | 158 | 351 | 41 | $1,788 |
| Mounjaro Tirzepatide | 150 | 182 | 27 | $190K |
| Kerendia Finerenone | 134 | 188 | 24 | $118K |
| Jardiance Empagliflozin | 116 | 180 | 23 | $92K |
| Atorvastatin Calcium Generic | 110 | 275 | 31 | $1,051 |
| Ozempic Semaglutide | 107 | 164 | 27 | $160K |
| Tresiba Flextouch U-200 Insulin Degludec | 80 | 167 | 16 | $74K |
| Trulicity Dulaglutide | 80 | 109 | 25 | $106K |
| Glipizide Generic | 75 | 150 | 19 | $802 |
| Tradjenta Linagliptin | 73 | 112 | 13 | $56K |
| Hydrocortisone Generic | 73 | 95 | Under 11 | $2,893 |
| Unithroid Levothyroxine Sodium | 73 | 121 | Under 11 | $3,914 |
| Metformin Hcl Er Metformin Hcl | 71 | 164 | 16 | $461 |
Brand drugs: 2,133 claims; generic drugs: 1,657 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Moazzam W Habib $2,711 ($2,711 in general payments such as food, travel and fees) from 23 companies. The largest payer was Corcept Therapeutics with $373.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 23 | $373 |
| Amgen Inc. AMGN | 18 | $309 |
| Novo Nordisk Inc NVO | 17 | $242 |
| Alexion Pharmaceuticals, Inc. AZN | 8 | $205 |
| Xeris Pharmaceuticals, Inc. | 9 | $165 |
| Esperion Therapeutics, Inc. ESPR | 10 | $151 |
| Mannkind Corporation MNKD | 7 | $148 |
| Endo USA, Inc. | 7 | $145 |
| Lilly USA, LLC LLY | 9 | $136 |
| Amneal Pharmaceuticals LLC AMRX | 9 | $136 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.